Prevalence, types, risk factors, and outcomes of cardiorenal syndrome in a rural population of central India: A cross-sectional study

Maria Prothasis¹, Anuj Varma¹, Shilpa Gaidhane¹, Sunil Kumar¹, Nazli Khatib^{2,3}, Quazi S. Zahiruddin^{4,5}, Abhay Gaidhane^{4,6}

Departments of ¹Medicine, ²Physiology and ⁴Community Medicine, ⁶Director, ³Faculty in Evidence Synthesis, ⁶Global Health, School of Epidemiology and Public Health, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe), Wardha, Maharashtra, India

ABSTRACT

Background and Objectives: Heart failure leading to renal dysfunction and vice-versa termed as Cardio-Renal Syndrome(CRS) has now been increasingly identified as a marker of higher morbidity and mortality. Till date, there is limited data available regarding clinical profile, associated risk factors and outcome of CRS in rural population of central India. This study was conducted to elucidate the prevalence, risk factors, and outcome of CRS and its types. Methods: This was a single-centric, cross-sectional study conducted amongst the patients admitted to medicine wards and ICCU from October 2017 to September 2019. Classification given by RONCO et al. in 2008 was used for classifying CRS patients into various types. Cross-sectional data was used to find the prevalence, risk factors and their inter-relationship with outcome and mortality. STATA software was used for statistical analysis. Results: Out of 96 CRS patients, 47(48.96%) were Type 1, 22 (22.92%) were type 2, 19(19.79%) were type 4 and 3 (3.13%) were type 3, and 5 (5.21%) were of type 5. Most common risk factor was Hypertension (HTN) found in 46 (47.92%), followed closely by Coronary Artery Disease (CAD) and anaemia. Mortality was seen in 44(45.83%) of CRS patients and it was significantly high. High mortality was common in patients of types 3 and type 5 CRS. Risk factors like HTN, CAD, smoking, reduced glomerular filtration rate, low ejection fraction and sepsis were significantly associated with worse outcomes across all CRS sub-types. Interpretation and Conclusions: There is high mortality among CRS. Prevention or optimal management of HTN, CAD and sepsis is required to decrease mortality. There is need for more population based studies for confirming our study findings.

Keywords: Cardio-renal syndrome, outcomes, risk factors, types

Introduction

Heart failure (HF) leading to renal dysfunction and vice-versa

Address for correspondence: Prof. Shilpa Gaidhane, Professor (Medicine), Jawaharlal Nehru Medical College, Faculty of Clinical Epidemiology, School of Epidemiology and Public Health, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe),

Wardha - 442 004, Maharashtra, India. E-mail: drshilpagaidhane@gmail.com

Received: 03-04-2020 **Revised:** 26-04-2020 **Accepted:** 08-05-2020 **Published:** 25-08-2020

Access this article online

Quick Response Code:



Website: www.jfmpc.com

DOI:

10.4103/jfmpc.jfmpc_533_20

is termed as cardiorenal syndrome (CRS).^[1] It is one of the poor prognostic indicators as CRS causes higher morbidity and mortality in patients suffering concomitantly from heart failure (HF) and acute kidney injury (AKI) or chronic kidney disease (CKD).^[2]

Reduced renal function seen in patients suffering from acute or chronic HF increases cardiovascular morbidity and mortality.^[3] Acute dialysis quality initiative quotes the existence of some

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Prothasis M, Varma A, Gaidhane S, Kumar S, Khatib N, Zahiruddin QS, *et al.* Prevalence, types, risk factors, and outcomes of cardiorenal syndrome in a rural population of central India: A cross-sectional study. J Family Med Prim Care 2020;9:4127-33.

form of renal dysfunction, i.e., CRS in 25% to 63% of patients suffering from HF.[3] Moreover, a majority of these patients develop varying levels of worsening renal function during the management of HF. In such patients, even a slight reduction in renal function is related to an exponential rise in mortality.^[3] Similarly, AKI or CKD may have a delirious effect on cardiac performance through various factors such as volume overload, negative inotropy, uncontrolled hypertension, and electrolyte imbalance being some of them. [4] Therefore, the patients having renal dysfunction are at a markedly higher risk for acute HF. It is found that in CKD patients, 43.6% of all deaths occur due to cardiac diseases.^[5] It is estimated that patients with CKD are found to have 10 to 20 times more likely possibilities to die from various cardiac diseases than their similar groups in the general population.^[5] CRS also carries its importance because there is increase in the geriatric population due to increased longevity, increase in incidence and prevalence of various cardiovascular and renal risk factors and also because of more number of younger population suffering from cardiac and renal diseases. [6]

Till date, few studies have been reported in western countries about the prevalence, types, and outcomes associated with mortality in patients of CRS.^[7-11] In India HR Shah *et al.*, had studied the clinical profiles and outcomes of CRS patients in North India. ^[6] Thus, there is still a paucity of studies regarding the prevalence and risk factors associated with various types of CRS and morbidity and mortality in Central India. ^[6-9] Moreover, there is increasing trends of cardiovascular diseases leading to heart failure and kidney diseases among rural population, which are catered by primary care physicians. ^[10,11] Hence, we conducted this study to estimate the prevalence, types, and outcomes (mortality, dialysis requirement, and duration of hospital stay) of CRS patients. Also, to find out the risk factors associated with mortality among CRS. Early identification of these risk factors may aid in reducing the morbidity and mortality due to CRS.

Material and Methods

Ethical approval

This study was started upon approval by the institutional ethics committee (vide IEC/2017-18/6755).

Study design

This single-centered cross-sectional study was conducted between October 2017 and September 2019 in patients admitted to medicine wards and ICCU which cater to the rural population of central India. The patients were enrolled in study after giving informed consent. Cross-sectional data was used to find the prevalence, risk factors and their interrelationship with outcome and mortality.

Data collection

During the study period, 215 patients were admitted with HF diagnosed as per Framhingham criteria. [12] Of these, 69 patients had deranged renal function and were identified as having AKI

or CKD based on the 2012 KDIGO guidelines^[13,14] for AKI and CKD and then were classified into type 1 and 2 CRS as per the classification of CRS given by Ronco *et al.* in 2008.^[1] Similarly, 254 patients were admitted with worsening renal function, of which 22 patients were diagnosed as having HF and then were classified into type 3 and 4 CRS. Fifty-six patients were admitted with systemic conditions such as sepsis (secondary to cellulitis, infections of lower respiratory tract, various infections of urinary tract), acute respiratory distress syndrome and systemic lupus erthyematosus, out of which five patients were diagnosed as having simultaneous dysfunction of both heart and kidneys and were classified into type 5 CRS. Thus, a total of 96 patients fulfilling the inclusion criteria, i.e., clinical history and examination suggestive of both cardiac and renal dysfunction, i.e., CRS were included in the study to prevent selection bias.

Patients' demographic details were recorded. A pilot-tested questionnaire was used to collect information regarding patient's sociodemographic profile, history of cardiovascular disease risk factors such as systemic hypertension, diabetes, dyslipidemia, history of cerebrovascular episode, hypothyroidism, and addictions in the form of alcohol and smoking. Clinical examination included anthropometric measurements, recording of blood pressure and respiratory rate, assessing mental status, detailed cardiovascular, respiratory and per abdomen examination. The quick Sepsis Related Organ Failure Assessment (qSOFA) score was used to identify patients with sepsis as it facilitates simple and approximate earliest identification of sepsis outside hospitals and wards.^[15] All patients were subjected for laboratory investigations which included CBC (complete blood count), KFT (kidney function test), FBS (fasting blood sugar), PMBS (post meal blood sugar), fasting lipid profile (including Total cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein).

Assessment of Cardiac Function: Cardiac dysfunction was identified as patients having HF as per the Framingham criteria, or with a history of ongoing treatment for HF. 2D echocardiography (ECHO) was done to estimate left ventricular ejection fraction which was calculated by using the SIMPSON'S formula.^[16]

Assessment of Renal Function: Renal function was studied using the levels of serum creatinine and estimated glomerular filtration rate (eGFR); the latter was calculated using MDRD equation and was used in staging of CKD. [17] Ultrasonography of kidney, ureter, and bladder was done in all patients to differentiate AKI from that of CKD. The echogenicity of renal cortex and differentiation of the cortex and medulla were assessed. The echogenicity of renal cortex was compared and graded with that of spleen and renal medulla and, thus, renal parenchymal disease was graded. [18]

Definitions

Definition and classification of CRS: We adopted the definition suggested by Ronco et al. in 2008 at a consensus conference under

Volume 9: Issue 8: August 2020

the patronage of the Acute Dialysis Quality Initiative (ADQI). Cardio renal syndrome is defined as "Disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other." CRS is classified into five types depending on whether kidney or heart was the initial organ of insult. [19] Accordingly, in type 1 and 2 CRS, worsening of acute HF (type 1) or chronic HF (type 2) leads to kidney dysfunction. In types 3 and 4 (termed acute and chronic renocardiac syndromes, respectively), consisting of AKI or CKD causes worsening of HF. In type 5 CRS, various systemic conditions cause simultaneous worsening of the heart and kidney.^[1]

Diabetes mellitus was defined as patients already on oral hypoglycemic agents, insulin, or newly diagnosed as per the 2017 guidelines of American Diabetic Association. [20] Patients who were on antihypertensive medications or diagnosed as per JNC7 criteria (Joint National Committee's seventh report) were defined as hypertensives. [21] Patients who have had past documented or present history of myocardial infarction, unstable angina, percutaneous coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) were classified as having CAD.

Statistical analysis

Data was presented as either mean (SD) or proportion. To study the association of risk factors with CRS, t-test or chi-square test of significance was used. Multiple regression analysis was used to study the independent association of risk factors with outcome of cardio renal syndrome. All the analysis was done by STATA version 14.

Results

Table 1 shows the baseline characteristics of our CRS patients in which majority belonged to the age above 60 years i.e., 51 (53.13%). The minimum age of our patients was 20 years and maximum was 81 years. In our study, males were more in number, i.e., 60% which may be due to the increase in the prevalence of CAD and cardiovascular risk factors such as HTN, diabetes and dyslipidemia. [6] The lowest eGFR was 4 ml/min




Figure 1: Prevalence of various types of CRS

and highest was 47 ml/min, lowest LVef was 15% and highest was 65%, and the minimum length of hospital stay was zero and maximum was 47 days.

The maximum number of patients of CRS, i.e., 46 (48.42%) had grade 1 RPD. More CRS patients were of stage 4 of CKD, i.e., 38 (39.58%) followed by stages 3B and 5.^[20] Type 1 CRS is the most common type followed by type 2 and 4 [Figure 1].

The most common risk factor found to be associated with patients of CRS in our study was HTN which is found in 46 (47.92%) of patients [Figure 2].

The most common risk factors were CAD in type 1 and 2 CRS, HTN and sepsis in type 3 CRS, and CKD in type 4 CRS, and sepsis in type 5 CRS [Table 2].

It was found that in type 1 and 2 CRS, the maximum number of patients were managed conservatively without dialysis. While in type 3 CRS, all patients were managed conservatively. In types 4 and 5, more number of patients were subjected to dialysis [Table 3].

Table 1: Baseline characteristics of patients of cardio-					
renal syndrome (CRS)					
Variables	Mean	Std. Dev.			
Age (years)	56.46	14.4			
Male No.(%)	58 (60.42%)				
Female No.(%)	38 (39.58%)				
Body Mass Index (BMI) (kg/m²)	23.22	3.66			
Waist circumference (cm)	83.19	4.89			
Hip circumference (cm)	95.98	4.31			
Waist Hip Ratio (WHR)	0.86	0.03			
Estimated Glomerular Filtration Rate	21.50	12.18			
(eGFR) (ml/min)	39.63	13.23			
Left ventricular ejection fraction (LVef) (%)		13.23			
Smoking; No.(%)	23 (23.96%)				
Alcohol; No.(%)	20 (20.83%)				
Length of stay at hospital in days	9.45	9.41			




Figure 2: Prevalence of risk factors among patients of CRS

Volume 9 : Issue 8 : August 2020

The outcome of the patients of CRS was studied in which 52 (54.16%) patients survived and were discharged from hospital in a stable condition. However, 44 (45.83%) of the study participants died which shows that mortality was significantly high in the patients of CRS in our study [Table 4].

In our study, the risk factors associated with mortality were age being more than 60 years, smoking, HTN, CAD, DM, sepsis, and laboratory parameters such as blood urea, serum creatinine, eGFR, and LVEF [Table 5].

In univariate analysis, eGFR, LVef, smoking, blood urea, serum creatinine, CAD, DM, and sepsis were the risk factors associated with mortality [Table 6]. In multivariate analysis, the risk factors associated independently with mortality were eGFR, blood urea, serum creatinine, and sepsis [Table 6].

Discussion

CRS has emerged as an important health issue due to the increase in various lifestyle disorders such as HTN, CAD, and DM. CRS

Table 2: Types of CRS with risk factors						
	TYPE 1 (n=47) No. (%)	TYPE 2 (n=22) No. (%)	TYPE 3 (n=3) No. (%)	TYPE 4 (n=19) No. (%)	TYPE 5 (n=5) No. (%)	P
HTN (n=46)	16 (34.04%)	13 (59.09%)	1 (33.33%)	13 (68.42%)	3 (60%)	chi ² =8.474 <i>P</i> =0.076
CAD (n=45)	28 (59.57%)	10 (45.45%)	0	6 (31.58%)	1 (20%)	chi ² =8.944 P=0.063
Hb $<$ 10 gm/dl (n =44)	16 (34.04%)	10 (45.45%)	0	16 (84.21%)	2 (40%)	chi ² =16.109 P=0.003
DM (n=33)	16 (34.04%)	11 (50%)	0	5 (26.31%)	1 (20%)	chi ² =4.959 P=0.291
CKD(n=19)	0	0	0	19 (100%)	0	chi ² =96.000 P=0.000
Sepsis(n=19)	8 (17.02%)	1 (4.55%)	1 (33.33%)	4 (21.05%)	5 (100%)	chi ² =24.077 P=0.000
Dyslipidemia (n=14)	7 (14.89%)	3 (13.65%)	0 (0%)	3 (15.79%)	1 (20%)	chi ² =0.671 P=0.955
Hypothyrodism (n=13)	6 (12.77%)	4 (18.18%)	0	3 (15.79%)	0	chi ² =1.7637 P=0.779
CVE (n=12)	6 (12.77%)	4 (18.18%)	0	1 (5.26%)	1 (20%)	chi ² (4)=2.2479 P=0.690

Hb: Haemoglobin CVE : Cerebro-Vascular episode

Table 3: Modality of treatment among various types of CRS						
	Type 1 (<i>n</i> =47) No. (%)	Type 2 (<i>n</i> =22) No. (%)	Type 3 (<i>n</i> =3) No. (%)	Type 4 (<i>n</i> =19) No. (%)	Type 5 (<i>n</i> =5) No. (%)	P
Haemodialysis (n=19)	3 (6.38%)	4 (18.18%)	0	9 (47.36%)	3 (60%)	chi ² =20.293 <i>P</i> =0.000
Conservative management (n=77)	44 (93.61%)	18 (81.81%)	3 (100%)	10 (52.63%)	2 (40%)	chi ² =20.293 <i>P</i> =0.000

Table 4: Comparison of outcomes among various types of CRS						
	Type 1 (<i>n</i> =47) No. (%)	Type 2 (<i>n</i> =22) No. (%)	Type 3 (<i>n</i> =3) No. (%)	Type 4 (<i>n</i> =19) No. (%)	Type 5 (<i>n</i> =5) No. (%)	P
Death (n=44)	20 (42.55%)	9 (40.9%)	3 (100%)	8 (42.10%)	4 (80%)	chi ² =6.4214 P=0.170
Survived (n=52)	27 (57.44%)	13 (59.09%)	0	11 (57.89%)	1 (20%)	chi ² =6.4214 P=0.170
Length of stay (mean+sd)	7.25 (7.06)	10.81 (9.69)	11.66 (3.21)	10.89 (10.95)	17.2 (18.30)	

Table 5: Risk factors associated with mortality					
	Mortality (n=44)	Survived (n=52)	P		
Age >60years (n=51)	29 (65.90%)	22 (42.31%)	chi ² =5.331 <i>P</i> =0.021 (s)		
Female $(n=38)$	17(38.64%)	21 (40.38%)	chi ² =0.030 <i>P</i> =0.861 (ns)		
Male (n=58)	27(61.36%)	31 (59.62%)			
BMI; (Mean±sd)	23.300±60	23.16 ± 0.46	0.849 (ns)		
WHR (Mean±sd)	0.86 ± 0.03	0.87 ± 0.03	0.1724 (ns)		
Smoking (n=23)	15 (34.04%)	8 (15.38%)	chi ² =4.577 <i>P</i> =0.032 (s)		
Alcohol (n=20)	9 (20.45%)	11 (21.15%)	chi ² =0.007 <i>P</i> =0.933 (ns)		
Hypertension (n=46)	16 (36.36%)	30 (57.69%)	chi ² =4.344 <i>P</i> =0.037 (s)		
Coronary artery disease (n=45)	15 (34.09%)	30 (57.69%)	$chi^2 = 5.33 P = 0.021 (s)$		
Anaemia (n=44)	19 (43.18%)	25 (48.07%)	chi ² =0.143 <i>P</i> =0.705 (ns)		
Diabetes Mellitus (n=33)	10 (22.72%)	23 (44.23%)	chi ² =4.885 <i>P</i> =0.027 (s)		
Sepsis (n=19)	16 (36.36%)	3 (5.76%)	chi ² =14.05 <i>P</i> =0.000 (s)		
Chronic kidney disease (n=19)	8 (18.18%)	11 (21.15%)	chi ² =0.1326 <i>P</i> =0.716 (ns)		
Dyslipidaemia (n=14)	6 (13.63%)	8 (15.38%)	chi ² =0.0585 <i>P</i> =0.809 (ns)		
Cerebro-vascular episode (n=12)	7 (15.9%)	5 (9.61%)	chi2=0.863 P=0.353 (ns)		

Table 6: Results of odds ratio univariate and multivariate analysis for predictors of mortality Univariate OR (95% CI) P Multi-variate OR (95% CI) P eGFR 0.97 (0.96-0.98) 0.96 (0.95-0.97) 0.01 0.002 1.03 (0.99-1.06) 1.02 (0.98-1.06) LVef 0.05 0.154 0.43 (0.13 1.42) 0.35 (0.13-0.93) Smoking 0.036 0.169 0.98 (0.97-0.99) 0.99 (0.98-0.99) Blood urea 0.007 0.010 Sr. Creatinine 0.97 (0.85-1.11) 0.95 (0.84-0.90) 0.01 0.003 1.27 (0.42-3.78) Coronary artery disease 2.63 (1.14-6.05) 0.022 0.665 Diabetes mellitus 2.69 (1.10-6.58) 2.42 (0.79-7.45) 0.121 0.029 Sepsis 0.10 (0.02-0.40) 0.10 (0.02-0.41) 0.002 0.001 Age 1.00 (0.98-1.03) 0.547 BMI 0.98 (0.88-1.10) 0.848 1.07 (0.47-2.44) Female 0.861 **FBS** 1.00 (0.99-1.01) 0.312 **PMBS** 1.00 (0.99-1.00) 0.531 HB 1.03 (0.86-1.24) 0.697 WHR 1.57 (0.67-3.63) 0.291Alcohol 1.04 (0.38-2.80) 0.933 Dyslipidemia 1.15 (0.36-3.61) 0.809 0.56 (0.16-1.91) 0.357

Table 7: Comparison of characteristics of CRS patients with other studies

Baseline characteristics	H R Shah et al. ^[6]	De Silva et al. ^[7]	Present study
Mean age (in years)	64.18±12.9	71±10.8	56.46±20.1
% males	66%	69 %	60.42%
eGFR	29.0±11.7	57±21	21.50 ± 12.18
LVef	31.70 ± 12.8	34.2 ± 10.2	39.63±13.23
Sr .creatinine	3.38 ± 2.18	9.0 ± 5.5	4.23±3.01
Haemoglobin	9.88 ± 2.33	13.11±6	10.00 ± 2.23

Table 8: Comparision of Risk factors associated with CRS and its types with other studies

Risk factors	H R Shah	Mavrakanas	Present
	et al. ^[6]	et al. ^[8]	study
Hypertension	78%	59 %	47.92%
Coronary Artery Disease	48%	60 %	46.88%
Anaemia	-	-	46.32%
Diabetes mellitus	64%	21.1 %	34.38%
Chronic Kidney Disease	50%	-	19.79%
Sepsis	-	-	19.79%
Dyslipidemia	44%	-	14.58%
Hypothyroidism	16%	-	13.54%

has an extremely poor prognosis^[17,22] with associated significant morbidity and mortality. Cardiac and renal dysfunctions often occur simultaneously because they share the common pathogenetic mechanisms.^[4] The pathophysiology of CRS is attributed to various hemodynamic and nonhemodynamic mechanisms some of which are decreased renal perfusion, increase in congestion of pulmonary and/or systemic circulation which in turn affects the perfusion of kidneys and/or sympathetic nervous system (SNS) activation , activation of RAAS, chronic inflammation and disproportionate production of nitiric oxide (NO) and reactive oxygen species (ROS).^[4] The

high prevalence of anemia in CRS may be caused by the increase in oxidative stress and reduction in the supply of oxygen to heart which causes a compensatory increase in heart rate and the stroke volume which then causes the activation of RAAS and SNS leading to vasoconstriction of renal vessels and retention of salt and water.^[23] Renal dysfunction may also be an adverse effect due to the management of HF with ACE-inhibitors, angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs), thiazides, and loop diuretics.^[24]

The present HF management is more targeted on improving the myocardial performance and hemodynamic balance, but they may have the potential consequences for causing renal dysfunction. Thus, it shows that the guidelines about optimal management of patients with CRS are still deficient. [25] There is often a dilemma in treating CRS as various life-saving medications such as ACE-inhibitors, ARBs, and MRAs are withheld in patients of CRS. At times, renal dysfunction also leads to diuretic resistance, thus complicating the management of CRS. [26]

Till date there is limited data available regarding clinical profile, associated risk factors, and outcomes of CRS in rural Indian population. Thus, our present study on the clinical profile of CRS was done which targeted to determine the prevalence of five types of CRS and the risk factors associated with their morbidity and mortality.

In our study, of the 96 patients with CRS, about half of the patients were of type 1 followed by types 2 and type 4. The most common risk factors associated with CRS were HTN, CAD, and anemia which were found in almost half of them. Regarding treatment modality, around one-fifth of patients were dialysed and four-fifth were given optimal medical management. Mortality was seen in almost half of the CRS patients which was significantly high. The high mortality was common in

Table 9: Comparison of types of CRS, treatment modality and outcome among CRS with other studies

Types of CRS	HR Shah et al.[6]	Present study
Type 1	46 %	48.96 %
Type 2	22 %	22.92%
Type 3	-	3.13 %
Type 4	26 %	19.79 %
Type 5	6 %	5.21 %
Treatment modality		
Dialysis	32 %	19.79 %
Optimal medical management	=	80.20 %
Outcome		
Death	16 %	45.83 %
Survived	52 %	54.16 %

patients wth types 3 and 5.CRS. Patients who succumbed were hypertensives, having CAD, low eGFR and reduced LVef.

Table 7 shows that most of the baseline characteristics of our study were comparable with the studies done by HR Shah *et al.*, and De Silva *et al.*^[6,7] However, in the study done in UK by De Silva *et al.*,^[7] the mean age was 71 years which was significantly higher than the Indian studies. This may be due to the fact that the cardiovascular disorder occurs in younger population in India compared to the other western countries.^[25] This lower age of presentation in our study can have significant effect on family economy as well as social stability.

The mean eGFR in the study done by De Silva *et al.*, ^[7] was higher as compared to our study indicating that renal involvement was more severe in our patients with CRS.

The mean hemoglobin levels in our study were lower compared to the study by De Silva *et al.*^[7] where the mean Hb was 13 gm/dl. This high prevalence of anemia can be attributed to severe renal involvement in our CRS patients. Moreover 60% of the study population were females, in whom anemia is more common. However, the mean haemoglobin levels were comparable to the study done in India by HR Shah *et al.*,^[6] which shows that the prevalence of anemia is more in Indian population as compared to the western population. This may even state that Indians are lacking behind in the prevention and optimal management of anemia. In a study done by RP Silva *et al.*,^[27] the prevalence of anemia in CRS patients was studied and they concluded that although anemia was more prevalent in CRS it was not associated with increase in mortality. This was similar to our study as although anemia was a common risk factor found, it was not associated with mortality.

Table 8 shows the comparison of risk factors in our study with the studies done by HR Shah *et al.*, and Mavrakanas *et al.*^[6,8] It is found that in the study done by HR Shah *et al.*, ^[6] HTN was present in 78% patients which was higher than our study and in the study by Mavrakanas *et al.*^[8] CAD was found to be higher, i.e., 60% which may be due to the fact that our study was done in rural population where the prevalence of CAD is lesser than the urban population.

Table 9 shows the comparison of types of CRS, treatment modalities used, and the outcomes of CRS patients. It was found that more number of patients, i.e., 32% of patients were dialysed in study by HR Shah *et al.*, ^[6] and this was associated with the lesser mortality in their study. In the study done by HR Shah *et al.*, ^[6] the mortality was 16% and 10.14% which was much lower as compared to our study.

In our study, the risk factors associated with mortality were age more than 60 years, smoking, HTN, CAD, DM, sepsis, and laboratory parameters such as blood urea, serum creatinine, eGFR, and LVEF. This was similar to the studies done by HR Shah et al., [6] where serum creatinine, eGFR and HTN, DM, and CAD, respectively, were identified as the risk factors found to be significantly associated with mortality. So to summarize the findings of the present CRS study among the rural population of central India, CRS is more common among people aged more than 60 years. The prevalence of type 1 CRS was the highest followed by the type 2 and type 4 CRS. The most common risk factor found in our study was HTN followed by CAD, DM, and anemia. One fifth of the patients of CRS in our study were dialysed. Mortality was very high (about half of the patients succumbed). Of the five types of CRS, types 3 and 5 were associated with higher mortality than the others. The risk factors like HTN, CAD, smoking, reduced eGFR, low ejection fraction and sepsis were significantly associated with worse outcomes across all types of CRS. We highlight that early detection and optimal management of HTN, CAD, and sepsis is required to decrease mortality. This can be prevented by the early identification and appropriate management of CRS patients.

There is need for more population as well as hospital-based studies for confirming our study findings.

Limitations and Recommendations

Our study was single-centeric with a small sample size. Cystatin C was not estimated due to the lack of facility at our institute. There may be selection bias and detailed treatment history was not recorded. So also, due to time constraints, follow-up of the patients after discharge was not done. Thus, more of follow-up studies evaluating the long-term outcome are recommended.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

- Ronco C, Happio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008;19:1527-39.
- Schrier RW. Cardiorenal versus renocardiac syndrome: Is there a difference? Nat Clin pract Nephrol 2007;3:637.
- 3. Ronco C, Di Lullo L. Cardiorenal syndrome in Western

Volume 9 : Issue 8 : August 2020

- countries: Epidemiology, diagnosis and management approaches. Kidney Dis (Basel) 2017;2:151-63.
- Di Lullo L, Bellasi A, Barbera V, Russo D, Russo L, Di Iorio B, et al. Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate. Indian Heart J 2017;69:255-65.
- Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: "Guyton revisited". Eur Heart J 2005;26:11-7.
- HR Shah, NP Singh, NP Aggrawal, D Snghania, LK Jha, A Kumar. Cardiorenal syndrome: Clinical outcome study. J Assoc Physicians India 2016;64:41-6.
- De Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: Contributing factors and relationship to prognosis. Eur Heart J 2006;27:569-581.
- 8. Mavrakanas TA, Khattak A, Singh K, Charytan DM. Epidemiology and natural history of the cardiorenal syndromes in a cohort with echocardiography. Clin J Am Soc Nephrol 2017;12:1624-33.
- 9. Pavan M. Incidence of acute cardiorenal syndrome type 3 in India. Iran J Kidney Dis 2014;8:42-5.
- 10. Costanzo MR. The cardiorenal syndrome in heart failure. Heart Fail Clin 2020;16:81-97.
- 11. Ishigami J1, Cowan LT, Demmer RT, Grams ME, Lutsey PL, Carrero JJ, *et al.* Incident hospitalization with major cardiovascular diseases and subsequent risk of ESKD: Implications for cardiorenal syndrome. J Am Soc Nephrol 2020;31:405-14.
- 12. Maestre A, Gil V, Gallego J, Aznar J, Mora A, Martín Hidalgo A. Diagnostic accuracy of clinical criteria for identifying systolic and diastolic heart failure: Cross sectional study. J Eval Clin Pract 2009;15:55-61.
- 13. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO clinical practice guideline. Kidney Int 2012;2:19-23.
- 14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter 2013:3:1-150.
- 15. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, *et al.* The third international consensus definitions for sepsis and septic shock (sepsis 3). JAMA 2016;315:801-10.
- 16. Armstrong WF. Feigenbaum's Echocardiography. 7th ed.

- Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2010. p. 785.
- 17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, *et al.* A new equation to estimate glomerular filtration rate. Ann Intern Med 2010;25:449-57.
- 18. Shivashankara V, Shivalli S, Pai BH, Acharya KD, Gopalakrishnan R, Srikanth V, *et al.* A comparative study of sonographic grading of renal parenchymal changes and estimated glomerular filtration rate (eGFR) using modified diet in renal disease formula. J Clin Diagn Res 2016;10:TC09-11.
- 19. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, *et al.* Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703-11.
- 20. American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care 2017;40:S11-24.
- 21. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, *et al.* 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20.
- 22. Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, *et al.* Treatment and outcomes of acute coronary syndromes in India (CREATE): A prospective analysis of registry data. Lancet 2008;371:1435-42.
- 23. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, *et al.* Heart disease and stroke statistics-2016 update. Circulation 2016;133:e38-360.
- 24. Silverberg DS, Wexler D, Blum M, Tchebiner J, Sheps D, Keren G, *et al.* The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization. Clin Nephrol 2002;58:S37-45.
- 25. Nodari S, Palazzuoli A. Current treatment in acute and chronic cardio-renal syndrome. Heart Fail Rev 2011;16:583-94.
- 26. Seth S, Khanal S, Ramakrishnan S, Gupta N, Bahl V. Epidemiology of acute decompensated heart failure in India: The AFAR study (Acute failure registry study). J Pract Cardiovasc Sci 2015;1:35-8.
- 27. Silva RP, Barbosa PH, Kimura OS, Sobrinho CR, Sousa Neto JD, Silva FA, *et al.* Prevalance of anemia and its association with cardiorenal syndrome. Int J Cardiol 2007;120:232-6.

Volume 9 : Issue 8 : August 2020